NCT05498636View on ClinicalTrials.gov

SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

July 30, 2025

Study Completion Date

December 31, 2025

Conditions
DLBCL
Interventions
COMBINATION_PRODUCT

Selinexor combined with Prednisone, Etoposide, and Lenalidomide

Selinexor combined with Prednisone, Etoposide, and Lenalidomide

Trial Locations (1)

266000

the affiliated hospital of Qingdao University, Qingdao

All Listed Sponsors
lead

The Affiliated Hospital of Qingdao University

OTHER

NCT05498636 - SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression | Biotech Hunter | Biotech Hunter